All Research Papers Published In Drug Resistance Updates

Research Article
10.1016/s1368-7646(25)00059-7

Editorial Board

Jul 01, 2025
Drug Resistance Updates

Research Article
33
10.1016/j.drup.2024.101154

E3 ubiquitin ligase DTX2 fosters ferroptosis resistance via suppressing NCOA4-mediated ferritinophagy in non-small cell lung cancer

Sep 28, 2024
Drug Resistance Updates
Zhuang Liu + 11 more +11

Research Article
21
10.1016/j.drup.2024.101146

Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma

Aug 30, 2024
Drug Resistance Updates
Ashu Shah + 9 more +9

Research Article
7
10.1016/j.drup.2024.101139

Fusion event mediated by IS903B between chromosome and plasmid in two MCR-9- and KPC-2-co-producing Klebsiella pneumoniae isolates

Aug 17, 2024
Drug Resistance Updates
Ruishan Liu + 8 more +8

Research Article
24
10.1016/j.drup.2024.101136

CBX4 counteracts cellular senescence to desensitize gastric cancer cells to chemotherapy by inducing YAP1 SUMOylation

Aug 12, 2024
Drug Resistance Updates
Yunru Gu + 12 more +12

Research Article
13
10.1016/j.drup.2024.101123

Emergence of silent NDM-1 carbapenemase gene in carbapenem-susceptible Klebsiella pneumoniae: Clinical implications and epidemiological insights

Jul 29, 2024
Drug Resistance Updates
Juanxiu Qin + 6 more +6

Research Article
3
10.1016/j.drup.2024.101121

Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China

Jul 14, 2024
Drug Resistance Updates
Shen Tian + 9 more +9

Research Article
35
10.1016/j.drup.2024.101116

A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis

Jul 03, 2024
Drug Resistance Updates
Jinan Guo + 19 more +19

Research Article
9
10.1016/j.drup.2024.101117

Circulating tumor cells with increasing aneuploidy predict inferior prognosis and therapeutic resistance in small cell lung cancer

Jul 02, 2024
Drug Resistance Updates
Zhongpeng Xie + 18 more +18

Research Article
49
10.1016/j.drup.2024.101103

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

Jun 25, 2024
Drug Resistance Updates
Antonino Glaviano + 20 more +20

Cell cycle dysregulation is a hallmark of cancer that promotes eccessive cell division. Cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key molecules in the G1-to-S phase cell cycle transition and are crucial for the onset, survival, and progression of breast cancer (BC). Small-molecule CDK4/CDK6 inhibitors (CDK4/6i) block phosphorylation of tumor suppressor Rb and thus restrain susceptible BC cells in G1 phase. Three CDK4/6i are approved for the first-line treatment of patients with advanced/metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) BC in combination with endocrine therapy (ET). Though this has improved the clinical outcomes for survival of BC patients, there is no established standard next-line treatment to tackle drug resistance. Recent studies suggest that CDK4/6i can modulate other distinct effects in both BC and breast stromal compartments, which may provide new insights into aspects of their clinical activity. This review describes the biochemistry of the CDK4/6-Rb-E2F pathway in HR+ BC, then discusses how CDK4/6i can trigger other effects in BC/breast stromal compartments, and finally outlines the mechanisms of CDK4/6i resistance that have emerged in recent preclinical studies and clinical cohorts, emphasizing the impact of these findings on novel therapeutic opportunities in BC.